Among the prespecified patient-reported outcomes ( @ patients on gefitinib and @ on placebo completed both baseline and @ week questionnaires and were included in analyses ) , odynophagia was significantly better in the gefitinib group ( adjusted mean difference -@ , @ % CI -@ to -@ ; n = @ ; p = @ ) , whereas the other outcomes were not significantly improved compared with placebo : global quality of life ( @ , @ % CI -@ to @ , n = @ , p = @ ) , dysphagia ( -@ , @ % CI -@ to @ , n = @ , p = @ ) , and eating ( -@ , @ % CI -@ to @ , n = @ , p = @ ) .